Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26704721 | 0.85 | CYP11B1 (0.68) | CYP11B1CYP11B2KDM4CLTA4HTNF | |
| SCHEMBL30167767 | 0.79 | HTR6 (0.45) | KDM4C | |
| SCHEMBL13508711 | 0.78 | CYP11B1 (0.65) | CYP11B1CYP11B2KDM4CLTA4HTNF | |
| SCHEMBL8131581 | 0.78 | MMP2 (0.54) | NR1I2ALDH1A1 | |
| SCHEMBL10468250 | 0.78 | TP53 (0.59) | CYP11B1CYP11B2KDM4CLTA4HTNF | |
| SCHEMBL31229302 | 0.77 | CYP11B1 (0.66) | CYP11B1CYP11B2KDM4CLTA4HTNF | |
| SCHEMBL22533680 | 0.76 | LTA4H (0.45) | CYP11B1CYP11B2KDM4CLTA4HTNF | |
| SCHEMBL30167601 | 0.76 | NAMPT (0.49) | KDM4C | |
| SCHEMBL8131955 | 0.75 | NR1I2 (0.46) | LTA4HNR1I2ALDH1A1 | |
| SCHEMBL27441902 | 0.75 | LTA4H (0.46) | CYP11B1CYP11B2KDM4CLTA4HTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | CYP11B1 535/4885CYP11B2 489/4885KDM4C 1563/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | CYP11B1 455/4885CYP11B2 427/4885KDM4C 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.